Payment overview · 2025
General Payments
$244.05
12 reported records · 5 companies
Healthcare provider profile · identity verified
Caisson Timber Hogue, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SUMMERVILLE, SC · NPI 1437230612
Verified facts
What the public records show
CMS Open Payments records show Caisson Timber Hogue, M.D. received $244.05 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.02 | 41.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.14 | 18.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.15 | 13.6% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $31.44 | 12.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.30 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.05 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.83 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.83 | 5 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $33.15 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $31.44 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 721 | 222 |
| Losartan Potassium | Losartan Potassium | 525 | 155 |
| Omeprazole | Omeprazole | 426 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 297 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 82 |
| Alprazolam | Alprazolam | 264 | 57 |
| Montelukast Sodium | Montelukast Sodium | 264 | 82 |
| Gabapentin | Gabapentin | 258 | 85 |
| Lisinopril | Lisinopril | 184 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 49 |
| Carvedilol | Carvedilol | 176 | 51 |
| Tramadol Hcl | Tramadol Hcl | 171 | 48 |
| Ozempic | Semaglutide | 160 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 47 |
| Ezetimibe | Ezetimibe | 145 | 43 |
| Metformin Hcl | Metformin Hcl | 145 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 34 |
| Simvastatin | Simvastatin | 123 | 37 |
| Celecoxib | Celecoxib | 121 | 40 |
| Eliquis | Apixaban | 121 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 58 |
| Glipizide Er | Glipizide | 117 | 33 |
| Lorazepam | Lorazepam | 112 | 26 |
| Sertraline Hcl | Sertraline Hcl | 111 | 36 |
| Furosemide | Furosemide | 107 | 40 |
| Trulicity | Dulaglutide | 100 | 21 |
| Farxiga | Dapagliflozin Propanediol | 97 | 22 |
| Azelastine Hcl | Azelastine Hcl | 96 | 44 |
| Testosterone Cypionate | Testosterone Cypionate | 96 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 23 |
| Pregabalin | Pregabalin | 94 | 29 |
| Allopurinol | Allopurinol | 92 | 27 |
| Clonazepam | Clonazepam | 92 | 16 |
| Mounjaro | Tirzepatide | 92 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 37 |
| Meloxicam | Meloxicam | 89 | 29 |
| Potassium Chloride | Potassium Chloride | 87 | 29 |
| Trazodone Hcl | Trazodone Hcl | 86 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 29 |
| Januvia | Sitagliptin Phosphate | 84 | 24 |
| Metformin Hcl Er | Metformin Hcl | 79 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 30 |
| Finasteride | Finasteride | 70 | 19 |
| Eszopiclone | Eszopiclone | 69 | 19 |
| Famotidine | Famotidine | 68 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 23 |
| Synthroid | Levothyroxine Sodium | 65 | 14 |
| Chlorthalidone | Chlorthalidone | 61 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 20 |
| Valsartan | Valsartan | 59 | 17 |
| Fenofibrate | Fenofibrate | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Bupropion Xl | Bupropion Hcl | 53 | 16 |
| Prednisone | Prednisone | 51 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Anastrozole | Anastrozole | 49 | 13 |
| Jardiance | Empagliflozin | 48 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 16 |
| Spironolactone | Spironolactone | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Atenolol | Atenolol | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 12 |
| Diazepam | Diazepam | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 32 | 13 |
| Azithromycin | Azithromycin | 31 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Estradiol | Estradiol | 31 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 12 |
| Naproxen | Naproxen | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.05 · 12 records | ABBVIE INC. | CLOTTRIEVER BOLD CATHETER, EVENITY, INTELLIS ADAPTIVESTIM, KRYSTEXXA, PROLIA, QULIPTA, SAPIEN 3 Ultra RESILIA, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error